H.C. Wainwright analyst Amit Dayal maintains a Buy rating on Amyris with an $11 price target after the company entered into a long-term agreement with Xinfu for an upfront payment of $50M and an additional long-term annual share upside based on an existing nutritional product royalty arrangement. Amyris is capitalizing on its relationship with Xinfu to monetize a portion of the long-term royalty opportunity upfront, which should lower quarterly volatility from this "high-margin" revenue stream while continuing to benefit from future royalty payments, Dayal tells investors in a research note. He thinks today's news should be viewed as a "timely delivery of a significant near-term milestone by the management team."